close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

66.65 -5.21 (-7.25%)
Streaming Delayed Price Updated: 1:02 PM EDT, Sep 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arrowhead Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
News headline image
Arrowhead Pharmaceuticals Spotlights Dual-Target RNAi Data, Plozasiran Launch Progress ↗
Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined early clinical data for its RNA interference dimer program, progress in the launch of plozasiran and plans for central nervous system and... 
Via MarketBeat
News headline image
Arrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline Expands ↗
Arrowhead Pharmaceuticals (NASDAQ:ARWR) is expanding its commercial and clinical footprint around RNA interference therapies, with its recently launched triglyceride-lowering treatment REDEMPLO and... 
Via MarketBeat
News headline image
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Flashes Bull Flag Breakout Setup with Top-Tier Technical Strength ↗
Via Chartmill
News headline image
Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million ↗
Perry's liquidity event comes as the Arrowhead stock price surged. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead’s Plozasiran Cuts Triglycerides, Pancreatitis Risk in Phase 3 Trials ↗
Arrowhead Pharmaceuticals (NASDAQ:ARWR) presented 12-month results from its Phase 3 SHASTA-3 and SHASTA-4 trials evaluating plozasiran in adults with severe hypertriglyceridemia, reporting substantial... 
Via MarketBeat
News headline image
Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock? ↗
A drug that didn't meet expectations in a trial is to blame. 
Via The Motley Fool
News headline image
Arrowhead Pharmaceuticals Q3 Earnings Call Highlights ↗
Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported positive Phase III results for plozasiran in severe hypertriglyceridemia (SHTG), accelerating plans for a supplemental New Drug Application and... 
Via MarketBeat
Topics Earnings
News headline image
Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Top movers analysis in the middle of the day on 2026-07-22: top gainers and losers in today's session. ↗
Via Chartmill
Gapping stocks in Wednesday's session ↗
Via Chartmill
These stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction ↗
Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined upcoming clinical catalysts, early commercial trends and pipeline priorities during a Jefferies fireside chat, with Chief Medical Officer... 
Via MarketBeat
News headline image
Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum ↗
Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives said the company is entering a key period marked by new regulatory approvals, early commercial progress for REDEMPLO and upcoming Phase 3 data in... 
Via MarketBeat
News headline image
Arrowhead Pharmaceuticals Eyes $4B REDEMPLO Opportunity as RNAi Pipeline Readouts Near ↗
Arrowhead Pharmaceuticals (NASDAQ:ARWR) is moving into a more commercial phase while continuing to expand its RNA interference pipeline, Chief Executive Officer Chris Anzalone said during a... 
Via MarketBeat
News headline image
Arrowhead (ARWR) Q2 2026 Earnings Transcript ↗
Arrowhead (ARWR) Q2 2026 Earnings Transcript 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.